Daewoong Pharmaceutical’s Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis

SEOUL, South Korea, Jan. 29, 2024 /PRNewswire/ — Daewoong Pharmaceutical’s Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis (IPF), a rare and debilitating disease. This first-in-class PRS inhibitor has recently received…